Abstract: The invention is directed to novel tablets comprising isoflavone-containing plant extract and water-insoluble polysaccharides, and methods of manufacturing them.
Type:
Grant
Filed:
May 23, 2002
Date of Patent:
December 30, 2003
Assignees:
Indena S.p.A., Johnson & Johnson Consumer Companies, Inc.
Inventors:
Min Michael He, Fang-Yu Liu, Joseph A. Fix, Martin Link, Maria L. Kang, Ezio Bombardelli
Abstract: A solid orally administrable pharmaceutical dosage form for the treatment of gastric disorders includes a first portion containing a therapeutically effective amount of a histamine H2-receptor antagonist, and a second portion immediately adjacent the first portion without an intervening barrier disposed between the first portion and the second portion, the second portion containing a therapeutically effective amount of an antacid. Physical separation of the active ingredients into two different portions without a separating barrier has been found sufficient to prevent degradation of the histamine H2-receptor antagonist due to contact with the antacid. The invention therefore provides stabilization of a histamine H2-receptor antagonist-antacid combination tablet which is comparable to known multiple portion tablets, but without an intervening barrier between the antacid portion and the histamine H2-receptor antagonist portion.
Abstract: A cleaning wipe comprising a water insoluable substrate, wherein the substrate is a nonwoven fabric which is impregnated with a cleaning composition.
Type:
Grant
Filed:
November 13, 2001
Date of Patent:
November 25, 2003
Assignee:
Colgate-Palmolive Company
Inventors:
Lamberta Suazon, Dawne Barry, John Fletcher, Karen Wisniewski, Barbara Thomas
Abstract: A reshapable hair styling composition comprising at least one (meth)acrylic copolymer comprising: (a) units derived from at least one monomer chosen from (meth)acrylate esters of branched and straight chain alkyl alcohols, (b) units derived from at least one monomer chosen from (meth)acrylate esters of saturated and unsaturated cyclic alcohols containing 6 to 20 carbon atoms, (c) optionally units derived from at least one monomer chosen from hydrophilic monomers, and (d) optionally units derived from at least one monomer other than (a), (b), and (c) monomers, wherein said at least one (meth)acrylic copolymer comprises units derived from at least four different monomers and wherein said composition provides a reshapable effect.
Type:
Grant
Filed:
June 22, 2001
Date of Patent:
November 11, 2003
Assignee:
L'Oreal S.A.
Inventors:
Isabelle Rollat, Henri Samain, Olivier Morel
Abstract: The invention relates to a coating for an intravascular implant that prevents hyperproliferative vascular disease after a mechanical injury, such as angioplasty. The coating includes first and second agents, with the first agent acting on a calcium independent cellular pathway and the second agent acting on a calcium dependent cellular pathway. In an exemplary embodiment, the first agent is rapamycin and the second agent is cyclosporine A. The agents can be incorporated in a polymeric agent and can be applied either directly to the implant or on top of a primer layer placed on the implant. A top coat can be applied to the therapeutic coating, if desired.
Abstract: A hyaluronic acid gel composition comprising hyaluronic acid and a polymer, which is substantially unmodified with a chemical cross-linking agent or a chemical modifying agent and which has a percentage dissolution of hyaluronic acid of 50% or lower in 12 hours in a neutral aqueous solution of 37° C.
Abstract: A clear personal care composition includes water, a volatile silicone, and a silicone polyether having a molecular weight greater than 1000 and an HLB greater than 4. The composition may be, for example, an antiperspirant or deodorant composition.
Abstract: The present invention provides novel “patch in a bottle” technology in which a fluid composition, e.g., an aerosol spray, is applied onto a surface as a fluid, but then dries to form a covering element, such as a patch, having a tack free outer surface covering an underlying adhesive that helps adhere the patch to the substrate. The fluid compositions have a unique chemical formulation that allows such composite patches to form in situ. Specifically, the fluid compositions include a tacky component, such as an adhesive, and a film-forming, non-tacky component. The non-tacky and tacky components are selected to be immiscible with each other so that the components undergo phase separation as the fluid composition dries.
Type:
Grant
Filed:
February 15, 2001
Date of Patent:
September 30, 2003
Assignee:
3M Innovative Properties Company
Inventors:
Patricia J. Andolino Brandt, Charles M. Leir, David J. Wirtanen
Abstract: A pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system, for the release of the active substance 17-&bgr;-estradiol, contained therein in dissolved form being between its saturation concentration in equilibrium with a gas phase of less than 10% relative air humidity and its saturation concentration in equilibrium with a gas phase of more than 90% relative air humidity, in all matrix levels and, if present, also in an adhesive layer, characterized in that the estradiol quantity contained in in the preparation amounts to at least three times the saturation solubility measured at 95% relative air humidity, and that the air enclosed in the package is adjusted to a relative air humidity between 5% and below 0.5%.
Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
Type:
Grant
Filed:
September 27, 2002
Date of Patent:
September 16, 2003
Assignee:
CV Therapeutics, Inc.
Inventors:
Andrew A. Wolff, Fiona Baker, John Langridge
Abstract: A method of treating living tissue includes applying to living tissue a biocompatible adhesive composition containing at least one alkyl ester cyanoacrylate monomer and a polymerization initiator or accelerator, wherein the polymerization initiator or accelerator is a quaternary amine.
Type:
Grant
Filed:
August 2, 2000
Date of Patent:
September 16, 2003
Assignee:
Closure Medical Corporation
Inventors:
Jerry Y. Jonn, John Bobo, Julian Quintero, Jon P. Moseley
Abstract: Dosage form unit is provided to deliver one or more beneficial agents into a fluid, such as liquid enteral nutritional product. The dosage form unit includes a core containing at least one beneficial agent, preferably a marker dye, which is dispersible in the fluid. The core also contains a compatible binding agent to bind the beneficial agent together. Additional components of the core may include a plasticizer, a standard flow agent, a lubricant, additional tableting aids and at least one hydrophilic agent. A latex coating encases the core. The latex coating includes a mixture containing a substantially hydrophobic base material, preferably formed from an emulsion of cellulose acetate microspheres, which is capable of defining a matrix-type membrane, and at least one hydrophilic component being dispersible in the fluid. A dispersible beneficial agent is preferred as one of the hydrophilic components of the latex coating to allow immediate release of the beneficial agent therefrom.
Type:
Grant
Filed:
May 10, 2001
Date of Patent:
September 16, 2003
Assignee:
Abbott Laboratories
Inventors:
Terrence B. Mazer, Joseph E. Walton, Barbara S. Arnholt, Monty L. Evans, Ronita K. Geckle, Daniel Hamilton, John J. Kropczynski, Jr., Frank A. Murawski, Larry G. Tucker, Sherri A. Walker, Michael V. Walsh, Rhonda Cole Walsh
Abstract: A dosage formulation for once daily administration prior to sleeping is described that provides an initial delay in pharmaceutical release followed by controlled release of the pharmaceutical. There is also provided a method for preparing a time specific delayed, controlled release formulation of dosage, which method includes coating a single pellet with at least one dosage layer, which is coated by at least one seal coat and at least one outer rate controlling layer of a water soluble polymer coat. The dosage formulation of this invention provides substantially a drug free interval of about 0 to 5 hours followed by a drug delivery interval at a rate permitting bioavailability thereof for up to about 24 hours following oral administration. A method of using the formulations of the present invention for the treatment of early morning pathologies is also described.
Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
Abstract: This invention relates to an anhydrous cosmetic composition comprising: (a) 15-33% of an external phase (also called the oil phase) which is made with at least one selected naphthalate organic ester; a volatile silicone based emulsifier; and a volatile silicone; and (b) 85-67% of an internal phase which is made with an active ingredient, such as an antiperspirant active, in a glycol solvent. For the external phase all or a major portion of what would have been a non-volatile silicone component has been replaced by the naphthalate ester. While a dimethicone copolyol is still included, the use of this particular naphthalate ester obviates the need for the use of any other non-ionic emulsifiers.
Abstract: The present invention relates to the prevention and treatment of atopic dermatitis and treatment of atopic dermatitis and other eczematous disorders by application of topical mast cell stabilizers including cromolyn sodium, nedocromil or lodoxamide, in a vehicle of a buffered isotonic saline solution (OCEAN®).
Abstract: A novel silicone gum and the use of a silicone gum such as diphenyldimethicone dissolved in a silicone oil for making a cosmetic of pharmaceutical compositions, particularly dermatological compositions, containing a fatty phase. Anb exemplary silicone oil is phenyltrimethicone. Also contemplated is the preparation of a cosmetic or pharmaceutical composition for skin care, in particular for the face or the body or for hair care.
Abstract: A novel oral pharmaceutical composition in the form of a stable flocculated suspension in water is described as comprising: megestrol acetate; at least one compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerol, and sorbitol; and a surfactant, wherein polysorbate and polyethylene glycol are not simultaneously present.
Type:
Grant
Filed:
April 30, 2002
Date of Patent:
July 15, 2003
Assignee:
Pharmaceutical Resources Inc.
Inventors:
Narayan Ragunathan, James C. Chao, Robert A. Femia, Malcolm S. F. Ross
Abstract: A novel oral pharmaceutical composition in the form of a stable flocculated suspension in water is described as comprising: megestrol acetate; at least one compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerol, and sorbitol; and a surfactant, wherein polysorbate and polyethylene glycol are not simultaneously present.
Type:
Grant
Filed:
January 9, 2001
Date of Patent:
July 15, 2003
Assignee:
Pharmaceutical Resources Inc.
Inventors:
Narayan Ragunathan, James C. Chao, Robert A. Femia, Malcolm S. F. Ross
Abstract: A method for the prophylaxes and treatment of psoriasis, allergies and auto-immune disorders of the skin, the treatment of sensitive skin, or a combination thereof, which comprises applying cis-6-hexadecenoic acid, or a salt or ester thereof.